Its goal is to ensure the continued worldwide standardization of TB surveillance, in the context of WHO’s End TB Strategy, the latest WHO guidelines on TB screening, prevention, diagnosis and treatment, and commitments made at the 2023 UN High-Level Meeting on TB.

A Stop TB Partnership-led delegation of TB survivors, researchers, communities and civil society representatives attended the Multi-stakeholder Hearing on AMR to push for the inclusion of TB in the upcoming AMR Political Declaration.

The guidance includes approaches to expanding the coverage, quality and impact of existing social protection programs to people affected by TB.

WHO releases consolidated guidelines on HIV-associated TB providing a single comprehensive source for the latest evidence-informed TB/HIV recommendations.

The new 2024 update of An Activist’s Guide to Rifapentine TB Preventive Treatment: 3HP and 1HP lays out what TB community advocates need to know about rifapentine-based TB preventive treatment.

Transparency on clinical trial costs must become the norm to improve access to medical products worldwide.

Safeguarding children against TB takes center stage with introduction of child-friendly formulation of rifapentine for short-course TB preventive treatment.

The dictionary aims to unify TB-related terminology and promote clearer communication by providing a common language for researchers, policy-makers, donors and affected communities.

On World TB Day, WHO is calling for action on several fronts to ensure that the commitments made to end TB are achieved. A special newsletter edition compiles all WHO advocacy activities and key resources released in the lead-up to World TB Day.

With less than a year to go until the 1/4/6x24 Campaign deadline, the Getting Better Faster: Delivering on the Promise of New TB Treatments report outlines both progress made and remaining gaps toward achieving 1/4/6x24.